newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.
biotech/news//MarketScreener
Vanda Pharmaceuticals shares were trading above previous 52-week highs in the after-hours market.
The FDA approved Vanda Pharmaceuticals' Nereus for preventing motion-induced vomiting.
KEY POINTS
Nereus is the first newly approved drug for motion sickness in over four decades.
Vanda shares rose nearly 13% in after-hours trading after the FDA approval announcement.
The stock surpassed its previous 52-week high, reaching $7.93 post-approval.
By Stephen Nakrosis
Shares of Vanda Pharmaceuticals were trading above previous 52-week highs in the after-hours market, following news that the U.S. Food and Drug Administration approved Nereus as a treatment to prevent vomiting induced by motion.
After the bell, the company's shares were trading nearly 13% higher, at $7.93. The stock previously hit a 52-week high of $7.46 on Dec. 29.
The company's shares finished the day's regular session with a 2.3% loss, closing at $7.03. Year to date, the stock is up over 46%.
Vanda said the approval is the first for a new pharmacologic treatment in motion sickness in over four decades.
Write to Stephen Nakrosis at [email protected]
(END) Dow Jones Newswires
12-30-25 1901ET